The development of disease-modifying therapies for amyotrophic lateral sclerosis (ALS) is a priority for researchers in this field. Two studies have independently identified plasma and cerebrospinal fluid biomarkers for ALS, and these biomarkers could provide a means of testing the efficacy of novel ALS drug treatments in future clinical trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia
BMC Neurology Open Access 17 February 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Turner, M. R., Kiernan, M. C., Leigh, P. N. & Talbot, K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 8, 94–109 (2009).
Mitchell, R. M., Simmons, Z., Beard, J. L., Stephens, H. E. & Connor, J. R. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 42, 95–103 (2010).
Ryberg, H. et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 42, 104–111 (2010).
Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389–1392 (2006).
Brettschneider, J., Petzold, A., Sussmuth, S. D., Ludolph, A. & Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 28, 852–856 (2006).
Süssmuth, S. D. et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74, 982–987 (2010).
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).
Steinacker, P. et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 65, 1481–1487 (2008).
Braak, H., Ludolph, A. C., Thal, D. R & Del Tredici, K. Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol. 120, 67–74 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ludolph, A. Urgently needed—biomarkers for amyotrophic lateral sclerosis. Nat Rev Neurol 7, 13–14 (2011). https://doi.org/10.1038/nrneurol.2010.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.196
This article is cited by
-
Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism
Neurotherapeutics (2016)
-
Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia
BMC Neurology (2013)